检索结果-南通市图书馆

维普期刊数据库博看期刊

Comparison of clinical features of nephrotic syndrome after haploidentical and matched donor hematopoietic stem cell transplantation

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2024年第4期137卷 478-480页

作者： Wei Sun Yuanyuan Zhang Yuhong Chen Yuqian Sun Yifei Cheng fengrong wang Huan Chen Yao Chen Chenhua Yan Xiaodong Mo Wei Han Lanping Xu Yu wang Xiaohui Zhang Kaiyan Liu Xiaojun Huang Peking University People’s Hospital Peking University Institute of HematologyNational Clinical Research Center for Hematologic DiseaseBeijing Key Laboratory of Hematopoietic Stem Cell TransplantationPeking UniversityBeijing 10004China

To the Editor:Allogeneic hematopoietic stem cell transplantation(allo-HSCT)is one of the most effective options for hematological ***,allo-HSCT treatment can cause serious ***-transplant kidney damage is an important *** this study,we retrospectively analyzed the frequency of nephrotic syndrome(NS)after allo-HSCT and compared the frequency and clinical characteristics of NS between haploidentical donor(HID)and matched donor(MD)HSCT(including matched sibling donors[MSD]and unrelated donors[URD]).

关键词： hematopoietic clinical matched

动脉粥样硬化临床前期中医证候特点及用药规律文献挖掘

在线全文

学校读者我要写书评

暂无评论

中医药导报 2024年第2期30卷 94-99,118页

作者：刘莉王凤荣辽宁中医药大学辽宁沈阳110847 大连大学附属中山医院辽宁大连116001 辽宁中医药大学附属医院辽宁沈阳110032

目的:探析动脉粥样硬化临床前期的中医证候特点及中药应用规律。方法:检索万方数据库(Wanfang Data)、中国生物医学文献数据库(CBM)、中国知网(CNKI)、维普(VIP)等数据库从建库至2023年5月中医药治疗动脉粥样硬化临床前期的研究,提取基... 详细信息

目的:探析动脉粥样硬化临床前期的中医证候特点及中药应用规律。方法:检索万方数据库(Wanfang Data)、中国生物医学文献数据库(CBM)、中国知网(CNKI)、维普(VIP)等数据库从建库至2023年5月中医药治疗动脉粥样硬化临床前期的研究,提取基本信息建立数据库,进行频数统计、关联规则分析、聚类分析、复杂网络分析。结果:纳入文献208篇,其中82篇报告了中医证型,126篇报告了中药处方。常见证型有湿痰证、痰瘀互结证、阴虚阳亢证、肝肾阴虚证、肾精亏虚证、血瘀证等。高频药物有丹参、川芎、黄芪、甘草、茯苓、半夏、水蛭、泽泻、三七等,药性多为寒、温,药味多为辛、甘、苦,归经多为肝经、脾经、肺经、肾经;关联规则分析得到10条二项关联,18条三项关联;聚类分析得到6类药物组合;复杂网络分析得到18个高频药物构成的核心药物群。结论:动脉粥样硬化临床前期的中医证候以本虚标实为主要特征,本虚多为阴虚、气虚,标实多为痰湿、血瘀、气滞,主要病变脏腑为肾、肝、脾,遣方用药以补虚益气、活血化瘀、化痰通络为主,并随症加减。

关键词：动脉粥样硬化临床前期中医药证候用药规律文献挖掘

基于网络药理学和分子对接法研究参七解郁方治疗双心疾病的分子机制

在线全文

学校读者我要写书评

暂无评论

安徽医药 2024年第5期28卷 909-914,I0005页

作者：刘莉王凤荣辽宁中医药大学研究生学院辽宁沈阳110847 大连大学附属中山医院老年病科辽宁大连116001 辽宁中医药大学附属医院心内科辽宁沈阳110032

目的通过网络药理学与分子对接法研究参七解郁方治疗双心疾病的潜在有效成分和作用通路。方法通过中药系统药理学数据库分析平台TCMSP和TCMID数据库查找该方所用药物的活性成分以及作用靶标,在Gene Cards数据库下载双心疾病靶点;以Strin... 详细信息

目的通过网络药理学与分子对接法研究参七解郁方治疗双心疾病的潜在有效成分和作用通路。方法通过中药系统药理学数据库分析平台TCMSP和TCMID数据库查找该方所用药物的活性成分以及作用靶标,在Gene Cards数据库下载双心疾病靶点;以String平台数据为基础,利用Cytoscape软件构建参七解郁方与双心疾病共同靶点的蛋白质-蛋白质相互作用网络(PPI);绘制“活性成分-靶点-通路”网络图;采用Auto Dock Tools工具进一步对接药物活性成分及可能作用的靶点。结果参七解郁方有89个主要活性成分,56个主要靶点,与30个信号通路有关。将度值大于5的前7个活性成分的分子配体与前5个靶点进行分子对接,结果显示活性成分与靶点分子对接能力均较好。结论参七解郁方通过多成分、多靶点、多通路参与双心疾病的治疗。

关键词：冠心病焦虑抑郁双心疾病参七解郁方网络药理学分子对接

同方期刊数据库

Electrochemical investigation on the formations of Dy-Ni alloy films in dimethylformamide

在线全文

学校读者我要写书评

暂无评论

Rare Metals 2002年第2期21卷 85-89页

作者： HE fengrong, wang Yu, LIU Guankun, and SA LichangSchool of Chemistry and Chemical Engineering, Zhongshan University. Guangzhou 510275, China School of Chemistry and Chemical Engineering Zhongshan University Guangzhou 510275

The elexctrochemical properties of Dy (III), Ni(II) + Ni(II) indimethylformamide were studied by cyclic voltammetry on Pt or Cuelectrode. Black, metallic lustered, compact and well adhesive Dy-Nialloy films can be co-deposited on Cu electrode bysweeping-potential-deposition method within some potentials. SEM,EDAX and XRD were used to analyze the alloy films. The Dy content inthe Dy-Ni alloy film is up to 56.91/100 (mass fraction) and the Dy-Ni alloy films are amorphous.

关键词： Dy-Ni alloy film dimethylformamide (DMF) Sweeping-potential-deposition-method induced coi-deposition

Reduced β2-GPI is associated with increased platelet aggregation and activation in patients with prolonged isolated thrombocytopenia after allo-HSCT

在线全文

学校读者我要写书评

暂无评论

Science China(Life Sciences) 2019年第7期62卷 921-929页

作者： Haixia Fu Jingzhong Zhao Lanping Xu Kaiyan Liu Yu wang Huan Chen Wei Han Jingzhi wang fengrong wang Xiaojun Huang Xiaohui Zhang Peking University People's Hospital Peking University Institute of HematologyBeijing 100044China Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Diseases Beijing 100044China Peking University People's Hospital Department of Clinical LaboratoryBeijing 100044China

We aimed to measure platelet function and its relationship with β2-GPI in prolonged isolated thrombocytopenia(PT) after allogeneic hematopoietic stem cell transplantation(allo-HSCT).Fifty-six patients with PT and 60 allo-HSCT recipients without PT(non-PT controls) were *** aggregation and activation,β2-GPI and anti-β2-GPI antibody levels,vWF antigen,and vWF activity were *** effect of β2-GPI on platelet aggregation was also measured ex *** showed that ADP-induced platelet aggregation significantly increased(39%±7.5% vs.23%±8.5%,P=0.032),and the platelet expression of both CD62 p(33.6%±11.6% vs.8.5%±3.5%,P<0.001) and PAC-1(42.4%±7.6% vs.6.8%±2.2%,P<0.001) was significantly higher in patients with PT than in those without *** lower β2-GPI levels(164.2±12 μg m L^-1 vs.234.2±16 μg mL^-1,P<0.001),higher anti-β2-GPI IgG levels(1.78±0.46 U mL^-1 vs.0.94±0.39 U mL^-1,P<0.001),and increased vWF activity(133.06%±30.50% vs.102.17%±25.90%,P<0.001) were observed in patients with PT than in those without *** ADPinduced platelet aggregation(n=116,r^2=-0.5042,P<0.001) and vWF activity(n=116,r^2=-0.2872,P<0.001) were negatively correlated with β2-GPI *** summary,our data suggested that platelet aggregation and activation were significantly higher in patients with PT than in those without PT,which might be associated with reduced β2-GPI *** reduced β2-GPI levels might be due to the existence of anti-β2-GPI IgG.

关键词： β2-GPI hematopoietic stem cell transplantation prolonged isolated thrombocytopenia platelet aggregation platelet activation

Minimal residual disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation

在线全文

学校读者我要写书评

暂无评论

Frontiers of Medicine 2019年第3期13卷 354-364页

作者： Xiaodong Mo Xiaohui Zhang Lanping Xu Yu wang Chenhua Yan Huan Chen Yuhong Chen Wei Han fengrong wang Jingzhi wang Kaiyan Liu Xiaojun Huang Peking University People's Hospital Peking University Institute of HematologyBeijing Key Laboratory of Hematopoietic Stem Cell TransplantationBeijing 100044China Peking-Tsinghua Centerfor Life Sciences Academy for Advanced Interdisciplinary StudiesPeking UniversityBeijing 100044China

The efficacy of minimal residual disease (MRD)-directed immunotherapy,including interferon-α (IFN-α) treatment and chemotherapy plus granulocyte colony-stimulating factor-primed donor leukocyte infusion (chemo-DLI),was investigated in patients with high-risk myelodysplastic syndrome (MDS) who were MRD-positive after allogeneic hematopoietic stem cell transplantation (allo-HSCT).High-risk MDS patients who received non-T-cell-depleted allo-HSCT at the Peking University Institute of Hematology and were MRD-positive after ailo-HSCT were studied (n =47).The MRD-positive status was considered if leukemia-associated aberrant immune phenotypes or Wilms' tumor gene 1 expression is present in a single bone marrow *** cumulative incidence of the relapse and non-relapse mortality 2 years after immunotherapy were 14.5% and 21.4% (P=0.377)and 9.1% and 0.0% (P=0.985) for patients in the IFN-α and chemo-DLI groups,*** probability of disease-free and overall survival 2 years after immunotherapy were 76.4% and 78.6% (P =0.891) and 84.3% and 84.6% (P=0.972) for patients in the IFN-α and chemo-DLI groups,*** MRD after immunotherapy was associated with poor ***,the MRD-directed immunotherapy was effective for patients with high-risk MDS who were MRD-positive after alIo-HSCT,and the efficacy was comparable between chemo-DLI and IFN-α treatment.

关键词： donor leukocyte infusion hematopoietic stem cell transplantation interferon-α minimal residual disease myelodysplastic syndrome

Interferon-α salvage treatment is effective for patients with acute leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Frontiers of Medicine 2019年第2期13卷 238-249页

作者： Xiaodong Mo Xiaohui Zhang Lanping Xu Yu wang Chenhua Yan Huan Chen Yuhong Chen Wei Han fengrong wang Jingzhi wang Kaiyan Liu Xiaojun Huang Peking University People’s Hospital Peking University Institute of HematologyBeijing Key Laboratory of Hematopoietic Stem Cell TransplantationBeijing 100044China Peking-Tsinghua Center for Life Sciences Academy for Advanced Interdisciplinary StudiesPeking UniversityBeijing 100044China

The efficacy of salvage interferon-α(IFN-α) treatment was investigated in patients with unsatisfactory response to minimal residual disease (MRD)-directed donor lymphocyte infusion (DLI)(n=24). Patients who did not become MRD-negative at 1 month after DLI were those with unsatisfactory response and were eligible to receive salvage IFN-α treatment within 3 months of DLI. Recombinant human IFN-α-2b injections were subcutaneously administered 2–3 times a week for 6 months. Nine (37.5%), 6 (25.0%), and 3 (12.5%) patients became MRD-negative at 1, 2, and>2 months after the salvage IFN-α treatment, respectively. Two-year cumulative incidences of relapse and non-relapse mortality were 35.9% and 8.3%, respectively. Two-year probabilities of event-free survival, disease-free survival, and overall survival were 51.6%, 54.3%, and 68.0%, respectively. Outcomes of patients subjected to salvage IFN-α treatment after DLI were significantly better than those with persistent MRD without IFN-α treatment. Moreover, clinical outcomes were comparable between the salvage DLI and IFN-α treatment groups. Thus, salvage IFN-α treatment may help improve the outcome of patients with unsatisfactory responses to MRD-directed DLI and could be a potential salvage treatment for these patients after allogeneic hematopoietic stem cell transplantation.

关键词： interferon-α hematopoietic stem cell transplantation minimal residual disease donor lymphocyte infusion

葡萄糖-6-磷酸脱氢酶缺乏对血液病患者异基因造血干细胞移植的影响

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中华血液学杂志 2024年第2期45卷 121-127页

作者：王佳付海霞张圆圆莫晓冬韩婷婷孔军孙于谦吕萌韩伟陈欢陈育红王峰蓉闫晨华陈瑶王景枝王昱许兰平黄晓军张晓辉北京大学人民医院北京大学血液病研究所国家血液系统疾病临床医学研究中心造血干细胞移植治疗血液病北京市重点实验室北京100044 安徽医科大学第二附属医院合肥230601

目的探讨葡萄糖-6-磷酸脱氢酶(G6PD)缺乏症患者和非G6PD缺乏症患者在异基因造血干细胞移植(allo-HSCT)过程中预处理毒性、移植并发症和生存的差异。方法收集2015年3月至2021年1月G6PD缺乏症患者在北京大学人民医院行allo-HSCT的连续病... 详细信息

目的探讨葡萄糖-6-磷酸脱氢酶(G6PD)缺乏症患者和非G6PD缺乏症患者在异基因造血干细胞移植(allo-HSCT)过程中预处理毒性、移植并发症和生存的差异。方法收集2015年3月至2021年1月G6PD缺乏症患者在北京大学人民医院行allo-HSCT的连续病例作为研究组。以1∶5的比例随机抽选同期接受allo-HSCT,且性别、年龄、疾病、移植方式匹配的非G6PD缺乏患者作为对照组。收集两组患者的临床资料,进行回顾性巢式病例对照研究。结果共7例G6PD缺乏患者进入研究组,35例非G6PD缺乏患者作为对照组。研究组7例G6PD缺乏患者中男6例,女1例,中位年龄37(2~45)岁,均无明显G6PD缺乏症相关临床症状;血液系统原发病包括急性髓系白血病3例、急性淋巴细胞白血病2例、重型再生障碍性贫血2例。移植后28 d内研究组所有患者均获得粒细胞植入,对照组粒细胞植入率为94.3%;研究组、对照组粒细胞植入中位时间分别为13(11~17)d、12(10~23)d(P=0.601),血小板植入中位时间分别为21(6~64)d、14(7~70)d(P=0.113)。研究组、对照组继发性移植物功能不良(PGF)发生率分别为42.9%(3/7)、8.6%(3/35)(P=0.036),巨细胞病毒(CMV)感染发生率分别为71.4%(5/7)、31.4%(11/35)(P=0.049),出血性膀胱炎发生率分别为57.1%(4/7)、8.6%(3/35)(P=0.005),细菌感染发生率分别为100.0%(7/7)、77.1%(27/35)(P=0.070),EB病毒(EBV)感染发生率分别为14.3%(1/7)、14.3%(5/35)(P=1.000),真菌感染发生率分别为14.3%(1/7)、25.7%(9/35)(P=0.497),移植后淋巴细胞增殖性疾病(PTLD)发生率分别为0%(0/7)、5.7%(2/35)(P=0.387)。结论合并G6PD缺乏的血液病患者可耐受常规allo-HSCT预处理方案,粒细胞、血小板可顺利植入,但移植后需警惕病毒感染、出血性膀胱炎及继发性移植物功能不良。

关键词：葡萄糖-6-磷酸脱氢酶缺乏症异基因造血干细胞移植并发症预后

Risk factors for chronic graft-versus-host disease after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation in acute myeloid leukemia

在线全文

学校读者我要写书评

暂无评论

Frontiers of Medicine 2019年第6期13卷 667-679页

作者： Meng Lv Xiaohui Zhang Lanping Xu Yu wang Chenhua Yan Huan Chen Yuhong Chen Wei Han fengrong wang Jingzhi wang Kaiyan Liu Xiaojun Huang Xiaodong Mo Peking University People’s Hospital Peking University Institute of HematologyNational Clinical Research Center for Hematologic DiseaseBeijing Key Laboratory of Hematopoietic Stem Cell TransplantationBeijing 100044China Peking-Tsinghua Center for Life Sciences Academy for Advanced Interdisciplinary StudiesPeking UniversityBeijing 100044China

Chronic graft-versus-host disease(cGVHD)is a major complication following unmanipulated haploidentical hematopoietic stem cell transplantation(haplo-HSCT).We aimed to identify the risk factors for cGVHD in patients who underwent anti-thymocyte globulin-based haplo-HSCT for acute myeloid leukemia(n=280).The diagnosis of cGVHD was in accordance with the National Institutes of Health consensus criteria.A total of 169 patients suffered from *** patients who had 3 loci mismatched had a higher 8-year incidence of cGVHD(total,66.0%vs.53.7%,P=0.031;moderate to severe,42.4%vs.30.1%,P=0.036)than the patients who had 1 to 2 loci *** patients who had maternal donors had a higher 8-year incidence of moderate to severe cGVHD(49.2%vs.32.9%,P=0.024)compared with the patients who had other *** patients who had grades III to IV acute GVHD(aGVHD)had higher 8-year incidence of cGVHD(total,88.0%vs.50.4%,P<0.001;moderate to severe,68.0%vs.27.0%,P<0.001)compared with the patients without *** multivariate analysis,grades III to IV aGVHD was the only independent risk factor for ***,further interventions should be considered in patients with severe aGVHD to prevent cGVHD.

关键词： acute graft-versus-host disease chronic graft-versus-host disease National Institutes of Health consensus criteria acute myeloid leukemia anti-thymocyte globulin